Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

BACKGROUND: The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex) for the management of treatment-resistant multiple sclerosis (MS) spasticity opened a new opportunity for many patients. The aim of our study was to describe Sativex effectiveness and adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Patti, F, Messina, S, Solaro, C, Amato, M P, Bergamaschi, R, Bonavita, S, Bruno Bossio, R, Brescia Morra, V, Costantino, G F, Cavalla, P, Centonze, D, Comi, G, Cottone, S, Danni, M, Francia, A, Gajofatto, A, Gasperini, C, Ghezzi, A, Iudice, A, Lus, G, Maniscalco, G T, Marrosu, M G, Matta, M, Mirabella, M, Montanari, E, Pozzilli, C, Rovaris, M, Sessa, E, Spitaleri, D, Trojano, M, Valentino, P, Zappia, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013116/
https://www.ncbi.nlm.nih.gov/pubmed/27160523
http://dx.doi.org/10.1136/jnnp-2015-312591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013116/
https://www.ncbi.nlm.nih.gov/pubmed/27160523
http://dx.doi.org/10.1136/jnnp-2015-312591

Ejemplares similares